← Back to Search

Platelet Rich Plasma

PRP Therapy for Infertility (PIER Trial)

N/A
Recruiting
Research Sponsored by Reproductive Medicine Associates of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 9 weeks gestational age
Awards & highlights

PIER Trial Summary

This trial will test whether a PRP infusion into the uterus can help infertile women with thin endometrium conceive via IVF.

Who is the study for?
This trial is for women who've had at least two unsuccessful frozen embryo transfers due to thin endometrial lining or canceled cycles. They must not have certain uterine anomalies, be using other proliferation therapies, or have a history of thrombosis. Women with recent unsuccessful transfers before January 1, 2017, are excluded.Check my eligibility
What is being tested?
The study tests if an intrauterine infusion of Platelet Rich Plasma (PRP) can increase the thickness of the endometrium and improve IVF outcomes compared to a normal saline solution in women with infertility issues related to thin endometrial lining.See study design
What are the potential side effects?
Potential side effects may include discomfort at the infusion site, bleeding, infection risk from the procedure itself, and possible allergic reactions to PRP components. However, specific side effects will depend on individual patient responses.

PIER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the proliferative phase of the frozen embryo transfer cycle
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the proliferative phase of the frozen embryo transfer cycle for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Endometrial Thickness during frozen embryo transfer
Secondary outcome measures
Sustained implantation rate

PIER Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Intervention GroupActive Control1 Intervention
an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group
Group II: Control GroupPlacebo Group1 Intervention
an intrauterine infusion of normal saline will be administered to this group

Find a Location

Who is running the clinical trial?

Reproductive Medicine Associates of New JerseyLead Sponsor
52 Previous Clinical Trials
37,772 Total Patients Enrolled
30 Trials studying Infertility
19,231 Patients Enrolled for Infertility

Media Library

Platelet Rich Plasma Intrauterine infusion (Platelet Rich Plasma) Clinical Trial Eligibility Overview. Trial Name: NCT05538338 — N/A
Infertility Research Study Groups: Intervention Group, Control Group
Infertility Clinical Trial 2023: Platelet Rich Plasma Intrauterine infusion Highlights & Side Effects. Trial Name: NCT05538338 — N/A
Platelet Rich Plasma Intrauterine infusion (Platelet Rich Plasma) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05538338 — N/A
Infertility Patient Testimony for trial: Trial Name: NCT05538338 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment permit patients of a younger age to participate?

"According to the criteria for entry into this medical trial, those aged 18-45 are eligible. Separately, there exist 14 trials catered towards minors and 33 studies open exclusively to senior citizens."

Answered by AI

How many participants are typically included in this trial?

"Affirmative. According to the clinicaltrials.gov database, this experiment is actively recruiting participants after it was first publicized on October 15th 2022 and edited most recently on October 19th 2022. This study requires 62 patients from a single trial site."

Answered by AI

Are qualified participants still accepted for this clinical experiment?

"Indeed, the information posted on clinicaltrials.gov attests to this trial's active recruitment efforts. It was originally made available in October 15th 2022 and its most recent update happened four days later. 62 candidates are presently expected to join from a single location."

Answered by AI

What qualifications are necessary to participate in this medical experiment?

"This trial is admitting sixty-two individuals aged between 18 and 45 that have received oxytocics. In order to be considered, participants must present a record of two cancelled embryo transfer cycles due to inadequate endometrial thickness or failure to reach sustained clinical pregnancy. Additionally, patients must demonstrate an endometrial lining no thicker than 6mm on prior unsuccessful transfers."

Answered by AI

Who else is applying?

What state do they live in?
Indiana
What site did they apply to?
Reproductive Medicine Associates of New Jersey
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

We have done 6 rounds of letrozole.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Platelet Rich Plasma for Insufficient Endometrium
2022. "Platelet Rich Plasma for Insufficient Endometrium". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05538338.
All > Infertility
~30 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top